Literature DB >> 3091807

Drug pharmacokinetics and the carbon dioxide breath test.

E A Lane, I Parashos.   

Abstract

The interrelationship of the pharmacokinetics of a drug and the expiration of carbon dioxide formed as a metabolite have been studied. The pharmacokinetic characteristics of the drug that affect the usefulness of the carbon dioxide excretion as a measure of liver function were examined by means of computer simulations. The parent drug extraction ratio, fraction demethylated, volume of distribution, and absorption rate of an oral dosage form all contribute to the carbon dioxide breath test result. A drug that would be a useful substrate when the carbon dioxide breath test is used as a probe for changes in liver function should be at least 50% metabolized by demethylation, have a hepatic extraction ratio of 0.2-0.5, and be administered in a form that is rapidly absorbed.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3091807     DOI: 10.1007/bf01059282

Source DB:  PubMed          Journal:  J Pharmacokinet Biopharm        ISSN: 0090-466X


  28 in total

1.  Disposition of aminopyrine, antipyrine, diazepam, and indocyanine green in patients with liver disease or on anticonvulsant drug therapy: diazepam breath test and correlations in drug elimination.

Authors:  G W Hepner; E S Vesell; A Lipton; H A Harvey; G R Wilkinson; S Schenker
Journal:  J Lab Clin Med       Date:  1977-09

2.  Assessment of aminopyrine metabolism in man by breath analysis after oral administration of 14C-aminopyrine. Effects of phenobarbital, disulfiram and portal cirrhosis.

Authors:  G W Hepner; E S Vesell
Journal:  N Engl J Med       Date:  1974-12-26       Impact factor: 91.245

3.  Pharmacokinetic profile of diazepam in man following single intravenous and oral and chronic oral administrations.

Authors:  S A Kaplan; M L Jack; K Alexander; R E Weinfeld
Journal:  J Pharm Sci       Date:  1973-11       Impact factor: 3.534

4.  Effects of nitrous oxide and methotrexate administration on hepatic methionine synthetase and dihydrofolate reductase activities, hepatic folates, and formate oxidation in rats.

Authors:  K A Black; T R Tephly
Journal:  Mol Pharmacol       Date:  1983-05       Impact factor: 4.436

5.  Expiratory measurement of maximal amino-pyrine demethylation in vivo: effect of phenobarbital, partial hepatectomy, protacaval shunt and bile duct ligation in the rat.

Authors:  B H Lauterburg; J Bircher
Journal:  J Pharmacol Exp Ther       Date:  1976-02       Impact factor: 4.030

6.  Aminopyrine demethylation kinetics. Use of metabolite exhalation rates as an index of enhanced mixed-function oxidase activity in vivo.

Authors:  J B Houston; G F Lockwood; G Taylor
Journal:  Drug Metab Dispos       Date:  1981 Sep-Oct       Impact factor: 3.922

7.  Reduction of hepatic tetrahydrofolate and inhibition of exhalation of 14CO2 formed from [dimethylamino-14C]aminopyrine in nitrous oxide-treated rats.

Authors:  K A Black; V Virayotha; T R Tephly
Journal:  Hepatology       Date:  1984 Sep-Oct       Impact factor: 17.425

8.  Assessment of the cytochrome P-448 dependent liver enzyme system by a caffeine breath test.

Authors:  H Wietholtz; M Voegelin; M J Arnaud; J Bircher; R Preisig
Journal:  Eur J Clin Pharmacol       Date:  1981       Impact factor: 2.953

9.  The caffeine CO2 breath test: dose response and route of N-demethylation in smokers and nonsmokers.

Authors:  A N Kotake; D A Schoeller; G H Lambert; A L Baker; D D Schaffer; H Josephs
Journal:  Clin Pharmacol Ther       Date:  1982-08       Impact factor: 6.875

10.  Comparison of different methods expressing results of the aminopyrine breath test.

Authors:  D A Schoeller; A L Baker; P S Monroe; P S Krager; J F Schneider
Journal:  Hepatology       Date:  1982 Jul-Aug       Impact factor: 17.425

View more
  3 in total

Review 1.  The erythromycin breath test for the prediction of drug clearance.

Authors:  L P Rivory; K A Slaviero; J M Hoskins; S J Clarke
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

Review 2.  Assessment of liver metabolic function. Clinical implications.

Authors:  J Brockmöller; I Roots
Journal:  Clin Pharmacokinet       Date:  1994-09       Impact factor: 6.447

3.  Interpretation of non-invasive breath tests using (13)C-labeled substrates--a preliminary report with (13)C-methacetin.

Authors:  J F Lock; P Taheri; S Bauer; H-G Holzhütter; M Malinowski; P Neuhaus; M Stockmann
Journal:  Eur J Med Res       Date:  2009       Impact factor: 2.175

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.